Bevacizumab Safe for Non-Small Cell Lung Cancer, Asymptomatic Brain Metastases

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal Clinical Cancer Research, researchers have found that bevacizumab plus first-line paclitaxel and carboplatin may be safe and effective for the treatment of patients with non-small cell lung cancer (NSCLC) and asymptomatic, untreated brain metastases.

For the prospective, phase 2 study, researchers sought to investigate the safety and efficacy of bevacizumab in chemotherapy-naive or pretreated patients with NSCLC and asymptomatic, untreated brain metastases. 

Researchers assigned 67 patients with stage IV non-squamous NSCLC and asymptomatic brain metastases to receive first-line bevacizumab 15mg/kg IV plus carboplatin AUC 6 and paclitaxel 200mg/m2 IV every 3 weeks, and 24 patients to receive second-line bevacizumab 15mg/kg IV plus erlotinib 150mg/day orally until disease progression or unacceptable toxicity.

Due to low enrollment in the second group, results were exploratory in that group only. Results showed that in the first-line bevacizumab group, the 6-month progression-free survival rate was 56.5% and the median progression-free survival was 6.7 months (95% CI: 5.7 - 7.1).

The median overall survival was 16.0 months and the objective response rate was 62.7%. The findings suggest that first-line bevacizumab plus paclitaxel and carboplatin may be safe and effective for patients with NSCLC and asymptomatic, untreated brain metastases.

Recent results on entecavir may change use of lamivudine prophylaxis in cancer patients with the hep
Bevacizumab plus first-line paclitaxel and carboplatin may be effective for NSCLC and asymptomatic brain metastases.
The phase II prospective, non-comparative BRAIN study (NCT00800202) investigated efficacy and safety of bevacizumab in chemotherapy-naive or pretreated patients with non-small-cell lung cancer (NSCLC) and asymptomatic untreated brain metastases, to provide data in this previously unexplored subgroup.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs